This test is most useful if any of these apply to you.
GABA helps regulate nerve-cell activity, but a urine result hasn't been validated as a measure of how much GABA your brain has available. If you're testing because of insomnia or anxiety, a low result cannot establish a brain deficiency or explain your symptoms.
For sleep, mood, and preventive health, urinary GABA is a research-stage marker. Small human studies have reported associations, but no urinary target or strategy for choosing treatment from this result has been shown to improve health outcomes.
Your body makes GABA from glutamate. Both are amino acids that also carry signals between nerve cells. GABA generally reduces nerve-cell activity in the mature brain, while glutamate generally increases it. GABA is also produced outside the brain.
Laboratory studies show that some bacteria isolated from the human gut can produce GABA. How much bacterial production contributes to an individual's urine result is unresolved. Urinary GABA reflects production, breakdown, and kidney handling without identifying each source's contribution.
This quantitative urine amino-acid measurement uses liquid chromatography with tandem mass spectrometry, or LC-MS/MS. The method separates compounds before identifying and measuring them. It measures free GABA in urine. Creatinine is a waste product made by muscles. Reporting GABA relative to urine creatinine helps account for dilution. A spot sample does not measure total daily GABA production.
In a small sleep-trial substudy, higher first-morning urinary GABA at week two was associated with lower insomnia and anxiety scores. This relationship wasn't present at baseline. The study did not establish that the urine change caused the symptom improvement or that testing could identify who would benefit.
A separate pilot included 25 people with Long COVID, eight with myalgic encephalomyelitis/chronic fatigue syndrome, and eight healthy controls. Across all participants, those reporting anxiety attacks had urinary GABA about a third lower than those without. GABA did not differ significantly between the three diagnostic groups. The study used second-morning urine and examined many compounds and symptoms, so this small observational finding needs confirmation before it can guide individual decisions.
A conference abstract described 87 adults with asthma and 17 healthy participants. Urinary GABA did not differ clearly according to whether someone had obstructive sleep apnea. Within the apnea group, larger overnight increases were associated with more breathing interruptions while sleeping on the back, and morning levels were associated with snoring duration.
That study used an antibody-based assay, a different analytical method from LC-MS/MS. Its exploratory associations don't establish that urinary GABA causes apnea, measures brain inhibition, or adds useful information to a sleep study.
A 2001 pilot study reported elevated urinary GABA in about half of the women with ovarian cancer. The authors proposed that increased tumor activity of an enzyme involved in GABA production could explain the finding. They did not prove that mechanism.
The study used its own approach to correcting for urine concentration and did not validate urinary GABA for cancer screening. The finding cannot tell you the chance of cancer after a high result, and an ordinary result cannot rule cancer out.
Some autism studies examine patterns across many urinary amino acids. A reported seven-marker urine panel did not include GABA, so its ability to distinguish study groups does not validate this test or show an imbalance of calming and stimulating signals in the brain.
Blood GABA is a separate measurement. A 2026 pooled analysis found no consistent difference between people with and without autism and judged the evidence too uncertain for screening or diagnosis. Neither those blood findings nor exploratory urine panels establish a role for urinary GABA in a developmental evaluation.
In about 1,900 older Spanish adults at high cardiovascular risk, higher plasma GABA was associated with lower mortality. GABA was one of the compounds weighted toward lower predicted risk in a score that combined 38 compounds. The combined score was subsequently evaluated in several US cohorts; that does not establish GABA alone as a validated mortality predictor.
Another study found lower serum GABA in women aged 60 to 80 who had osteoporotic fractures. These are blood findings. Neither study measured urinary GABA or showed that raising GABA prevents fractures or extends life.
A published case of an infant taking vigabatrin illustrates a separate problem: the drug interfered with tryptophan measurement on an older amino-acid analyzer, while urinary GABA was also increased. The large disagreement concerned tryptophan, so it does not show that GABA results routinely differ by the same amount between methods.
Repeated measurements can show whether urinary excretion changed under comparable collection conditions. A reproducible change still needs a clinical explanation. There is no validated rule that a rising value means recovery, that a falling value means deterioration, or that tracking this marker improves preventive care.
Evidence-backed interventions that affect your GABA (Amino Acid) level
GABA (Amino Acid) is best interpreted alongside these tests.
GABA (Amino Acid) is included in these pre-built panels.
A comprehensive at-home nutritional and metabolic assessment that analyzes key biomarkers to reveal functional nutrient needs and imbalances.